HeikoSchoderMD

Nuclear Medicine • New York, NY

MSKCC

Join to view full profile

Dr. Schoder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schoder's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10021
Phone+1 212-639-7373

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Nuclear Medicine, 1998 - 2000
Humboldt University of Berlin - Charite Faculty of MedicineClass of 1989

Certifications & Licensure

NY State Medical License 2000 - 2026
CA State Medical License 2000 - 2025
NJ State Medical License 2006 - 2025
American Board of Nuclear Medicine Nuclear Medicine
CBNCNuclear Cardiology

Clinical Trials

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors Start of enrollment: 2005 Jun 01
Completed
Phase 1
The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules Start of enrollment: 2004 Mar 01
Completed
Not Applicable
The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer Start of enrollment: 2006 Apr 25
Completed
Not Applicable
Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients Start of enrollment: 2004 Jun 01
Completed
Not Applicable
Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis Start of enrollment: 2010 Jan 01
Terminated
Not Applicable
Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images Start of enrollment: 2010 Apr 01
Terminated
Prognostic Value of Rb-82 PET Myocardial Perfusion Imaging Start of enrollment: 2011 Nov 08
Completed
Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy Start of enrollment: 2014 May 01
Withdrawn
Not Applicable
A Study to Assess Thymic Function Using PET/CT and MRI Start of enrollment: 2016 Aug 01
Completed
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors Start of enrollment: 2018 Mar 07
Active, not recruiting
Phase 1
Imaging With a PET Agent for Detection of Cancers of the Head and Neck Start of enrollment: 2018 Aug 10
RECRUITING
PHASE1, PHASE2
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer Start of enrollment: 2019 Jul 19
Active, not recruiting
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People with HPV-Positive Throat Cancer Start of enrollment: 2022 Aug 04
RECRUITING
PHASE2
Roles: Contact
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People with Pancreatic Cancer Start of enrollment: 2021 Nov 18
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Roles: Contact, Principal Investigator
A Dye for the Detection of Cancer of the Tongue and Mouth Start of enrollment: 2017 Mar 15
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.
Magdalena Corona, Andrew Ip, Samantha Brown, Alejandro Luna, Hazim Khatib
Bone Marrow Transplantation. 2025-02-01
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma.
Jae H Park, M Lia Palomba, Karlo Perica, Sean M Devlin, Gunjan Shah
Journal of Clinical Oncology. 2025-01-30
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
Jennifer K Lue, Efrat Luttwak, Alfredo Rivas-Delgado, Helen Irawan, Alexander Boardman
Blood Cancer Journal. 2024-10-14

Journal Articles

CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET
David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Abstracts/Posters

High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
Heiko Schoder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Heiko Schoder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
Heiko Schoder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Heiko Schoder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
Heiko Schoder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Molecular Imaging in Diagnosis & Therapy, Personalized Treatment of Cancer
International Institute for Continuing Medical Education, Inc. (IICME), Williamsburg, Virginia - 9/7/2012